Armata Pharmaceuticals, Inc.

ARMP · NYSE · SIC 2836: Biological Products, (No Diagnostic Substances)
445
SEC Filings

Business Summary

Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Its pipeline includes AP-PA02, an inhaled phage targeting Pseudomonas aeruginosa in cystic fibrosis, and AP-SA02, targeting Staphylococcus aureus. The company has completed three Phase 2 randomized, double-blind, placebo-controlled clinical trials and operates a cGMP-compliant bacteriophage manufacturing facility in Los Angeles.

Next Earnings

Q2 FY2026 — expected 2026-09-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionARMPdiscussed_in_filing Artificial Intelligence
topic_mentionARMPdiscussed_in_filing Cybersecurity
topic_mentionARMPdiscussed_in_filing Trusted Computing
topic_mentionARMPdiscussed_in_filing Blockchain & Crypto
topic_mentionARMPdiscussed_in_filing Regulation
topic_mentionARMPdiscussed_in_filing Healthcare & Bio
topic_mentionARMPdiscussed_in_filing Platform & Ecosystem
topic_mentionARMPdiscussed_in_filing Sovereign & Government
topic_mentionARMPdiscussed_in_filing Artificial Intelligence
topic_mentionARMPdiscussed_in_filing Cybersecurity
topic_mentionARMPdiscussed_in_filing Trusted Computing
topic_mentionARMPdiscussed_in_filing Blockchain & Crypto
topic_mentionARMPdiscussed_in_filing Regulation
topic_mentionARMPdiscussed_in_filing Healthcare & Bio
topic_mentionARMPdiscussed_in_filing Platform & Ecosystem
topic_mentionARMPdiscussed_in_filing Sovereign & Government
topic_mentionARMPdiscussed_in_filing Artificial Intelligence
topic_mentionARMPdiscussed_in_filing Cybersecurity
topic_mentionARMPdiscussed_in_filing Trusted Computing
topic_mentionARMPdiscussed_in_filing Blockchain & Crypto

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-252025-12-310001104659-26-034532EDGAR78K words
2025-03-212024-12-310001558370-25-003406EDGAR—
2024-03-212023-12-310001558370-24-003706EDGAR—
2023-03-162022-12-310001558370-23-004014EDGAR—
2022-03-172021-12-310001558370-22-003845EDGAR—
2021-03-182020-12-310001558370-21-003202EDGAR—
2020-03-192019-12-310001558370-20-002943EDGAR—
2019-03-252018-12-310001144204-19-015711EDGAR—
2018-03-142017-12-310001144204-18-014652EDGAR—
2017-03-272016-12-310001144204-17-016833EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001104659-25-110383EDGAR24K words
2025-08-122025-06-300001558370-25-011235EDGAR—
2025-05-142025-03-310001558370-25-007765EDGAR—
2024-11-132024-09-300001558370-24-015530EDGAR—
2024-08-132024-06-300001558370-24-012061EDGAR—
2024-05-072024-03-310001558370-24-007068EDGAR—
2023-11-142023-09-300001558370-23-019036EDGAR—
2023-08-142023-06-300001558370-23-014701EDGAR—
2023-05-112023-03-310001558370-23-009372EDGAR—
2022-11-092022-09-300001558370-22-017141EDGAR—
2022-08-112022-06-300001558370-22-013269EDGAR—
2022-05-122022-03-310001558370-22-008532EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001104659-26-039180EDGAR1K words
2026-03-250001104659-26-034523EDGAR—
2026-03-190001104659-26-031715EDGAR—
2026-02-230001104659-26-018333EDGAR—
2026-01-260001104659-26-006446EDGAR—
2026-01-130001104659-26-003076EDGAR—
2025-12-010001104659-25-117387EDGAR—
2025-11-120001104659-25-110351EDGAR—
2025-10-220001104659-25-101447EDGAR—
2025-09-110001104659-25-089150EDGAR—

445 total filings indexed. 413 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

antibiotic-resistant-bacterial-infections cystic-fibrosis chronic-pulmonary-disease acute-systemic-bacterial-infections current-good-manufacturing-practices-(cgmp)

Company Identity

CIK0000921114
TickerARMP
ExchangeNYSE
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedWA
HeadquartersLos Angeles, California

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: d5c93c06d163d61d283d6060eed0d9c524aea65e41c2262de381644fbabaffae
parent: 6a4ccae5b70bc3641f5c32218b03e7744ec63e837b9ac3e210fdc70f3932d54c
content hash: 6d34d054189671caad065bf138a149f46077884be6753df20a2cbf72c398d887
signed: 2026-04-13T04:43:43.643Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf